Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B

BACKGROUND: Hepatitis B virus (HBV) infection is still a worldwide disease, which may cause liver cirrhosis or even hepatocellular carcinoma. Telbivudine is a potent nucleoside analogue used in the treatment of chronic hepatitis B (CHB); however, drug resistance has remained a challenge. As early vi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zhou, Rui, Zhou, Yuan-Ping, Lin, Chun, Gao, Hai-bing, Huang, Shui-wen, Huang, Zu-xiong, Sun, Fang, Lin, Yong, Zhang, Dong-qing, Lin, Qing-feng, Ao, Wen, Pan, Chen
Format: Artigo
Idioma:Inglês
Publicat: Kowsar 2013
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3877653/
https://ncbi.nlm.nih.gov/pubmed/24403918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5812/hepatmon.15573
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars